[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:alk-pathway":3},{"name":4,"total":5,"recruiting":6,"trials":7},"ALK Pathway",6,5,[8,16,23,29,36,42],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04923126","SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:14:59.425132Z","2026-05-05T02:43:28.957186Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05804227","Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas",[20],"Early Phase 1","2026-08-26T02:18:00.873391Z","2026-05-05T02:43:27.946570Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06833008","A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours",[12],"2026-08-26T02:16:46.147215Z","2026-05-05T02:43:27.288693Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT05557045","A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815",[33],"Phase 1","2026-08-26T02:15:25.633039Z","2026-04-29T02:57:57.148364Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT05886920","A Phase 1\u002F2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations",[12],"2026-08-26T02:16:46.951087Z","2026-06-14T18:39:22.238145Z",{"nct_id":43,"title":44,"phases":45,"status":47,"updated_at":48,"content_modified":49},"NCT07629167","Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway",[46],"Phase 2","NOT_YET_RECRUITING","2026-08-26T02:19:17.380174Z","2026-06-06T00:48:49.540453Z"]